WO2004005346A8 - Recepteur de l'hormone nucleaire - Google Patents

Recepteur de l'hormone nucleaire

Info

Publication number
WO2004005346A8
WO2004005346A8 PCT/GB2003/002848 GB0302848W WO2004005346A8 WO 2004005346 A8 WO2004005346 A8 WO 2004005346A8 GB 0302848 W GB0302848 W GB 0302848W WO 2004005346 A8 WO2004005346 A8 WO 2004005346A8
Authority
WO
WIPO (PCT)
Prior art keywords
hormone receptor
nuclear hormone
human nuclear
protein
termed
Prior art date
Application number
PCT/GB2003/002848
Other languages
English (en)
Other versions
WO2004005346A3 (fr
WO2004005346A2 (fr
Inventor
Christopher Benjamin Phelps
Richard Joseph Fagan
Janet Marjorie Allen
Kathryn Elizabeth Allen
Ilana Stancovski
Valerie Nathalie Pierron
Tom Phillips
Caroline Ann Hunt
Zinat Ellaheh Enayat
Original Assignee
Inpharmatica Ltd
Christopher Benjamin Phelps
Richard Joseph Fagan
Janet Marjorie Allen
Kathryn Elizabeth Allen
Ilana Stancovski
Valerie Nathalie Pierron
Tom Phillips
Caroline Ann Hunt
Zinat Ellaheh Enayat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inpharmatica Ltd, Christopher Benjamin Phelps, Richard Joseph Fagan, Janet Marjorie Allen, Kathryn Elizabeth Allen, Ilana Stancovski, Valerie Nathalie Pierron, Tom Phillips, Caroline Ann Hunt, Zinat Ellaheh Enayat filed Critical Inpharmatica Ltd
Priority to EP03738307A priority Critical patent/EP1520023A2/fr
Priority to AU2003244831A priority patent/AU2003244831A1/en
Publication of WO2004005346A2 publication Critical patent/WO2004005346A2/fr
Publication of WO2004005346A8 publication Critical patent/WO2004005346A8/fr
Publication of WO2004005346A3 publication Critical patent/WO2004005346A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne la protéine dénommée BAB13403.1 identifiée, en l'occurrence, comme contenant le domaine de liaison ligand-récepteur de l'hormone nucléaire et l'utilisation de cette protéine et de cette séquence d'acide nucléique issue du gène codant aux fins de diagnostic, la prévention et le traitement de maladies.
PCT/GB2003/002848 2002-07-03 2003-07-03 Recepteur de l'hormone nucleaire WO2004005346A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP03738307A EP1520023A2 (fr) 2002-07-03 2003-07-03 Recepteur de l'hormone nucleaire
AU2003244831A AU2003244831A1 (en) 2002-07-03 2003-07-03 Human nuclear hormone receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0215406A GB0215406D0 (en) 2002-07-03 2002-07-03 Protein
GB0215406.0 2002-07-03

Publications (3)

Publication Number Publication Date
WO2004005346A2 WO2004005346A2 (fr) 2004-01-15
WO2004005346A8 true WO2004005346A8 (fr) 2004-03-25
WO2004005346A3 WO2004005346A3 (fr) 2004-04-29

Family

ID=9939789

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/002848 WO2004005346A2 (fr) 2002-07-03 2003-07-03 Recepteur de l'hormone nucleaire

Country Status (4)

Country Link
EP (1) EP1520023A2 (fr)
AU (1) AU2003244831A1 (fr)
GB (1) GB0215406D0 (fr)
WO (1) WO2004005346A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2941385B1 (fr) 2009-01-23 2011-04-01 Millipore Corp Procede pour fournir un circuit pour liquide biologique et circuit obtenu.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383592A1 (fr) * 1999-03-31 2000-10-05 Curagen Corporation Acides nucleiques comprenant des phases de lecture ouverte codant des polypeptides; orfx
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides

Also Published As

Publication number Publication date
GB0215406D0 (en) 2002-08-14
EP1520023A2 (fr) 2005-04-06
AU2003244831A8 (en) 2004-01-23
AU2003244831A1 (en) 2004-01-23
WO2004005346A3 (fr) 2004-04-29
WO2004005346A2 (fr) 2004-01-15

Similar Documents

Publication Publication Date Title
IL169367A0 (en) Defensin proteins
WO2003054012A3 (fr) Leptines
WO2006046073A3 (fr) Proteine du type c1q
WO2004081199A3 (fr) Nouvelles compositions et methodes de traitement de troubles du systeme immunitaire
WO2004096856A3 (fr) Famille de proteines secretees
WO2002070563A3 (fr) Domaine de liaison de ligand au recepteur hormonal nucleaire
WO2006043060A3 (fr) Proteine contenant le domaine mam
IL169256A (en) Polypeptide having metalloprotease activity, nucleic acid encoding it and pharmaceutical composition comprising it
WO2004005346A8 (fr) Recepteur de l'hormone nucleaire
WO2002070558A3 (fr) Domaine de liaison du ligand du recepteur hormonal nucleaire
WO2004003010A3 (fr) Recepteur hormonal nucleaire
WO2004050703A8 (fr) Variant d'epissage de l'hormone de croissance hypophysaire humaine
WO2004003011A3 (fr) Recepteur hormonal nucleaire
WO2004009633A8 (fr) Recepteur de serotonine
WO2004101618A3 (fr) Proteines associees au recepteur de progestine yol002c-cgi-45
WO2001064875A3 (fr) Nouveaux transporteurs humains 20685, 579, 17114, 23821, 33894 et 32613
WO2004000882A3 (fr) Proteines
WO2004056863A3 (fr) Variante d'epissage
WO2002033058A3 (fr) Proteases a cysteine
WO2002046380A3 (fr) Proteine kinase
WO2007049062A3 (fr) Protéines contenant des domaines vwfa
WO2004024762A3 (fr) Proteine de type il-8
WO2004016654A8 (fr) Proteine du type il-8
WO2005085285A3 (fr) Recepteurs hormonaux nucleaires
WO2002062845A3 (fr) Molecules d'adhesion

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 03/2004 REPLACE "(71) APPLICANT (FOR US ONLY)" BY "(72) INVENTOR; AND (75) INVENTOR/APPLICANT (FOR US ONLY)"; UNDER (72, 75) IN THE ADDRESS OF "FAGAN, RICHARD, JOSEPH" REPLACE "IMPHARMATICA LIMITED" BY "INPHARMATICA LIMITED"

WWE Wipo information: entry into national phase

Ref document number: 2003738307

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003738307

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003738307

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP